首页> 外国专利> 2. The procedure for extracting EC from the action plan. It has pharmacological effects and uses

2. The procedure for extracting EC from the action plan. It has pharmacological effects and uses

机译:2.从行动计划中提取EC的程序。具有药理作用和用途

摘要

1. The procedure of preparing one or more soaking agents, which are characterized in that these soaking agents are fermented and synthesized into a medium containing actin sp;Until one or more soaks are accumulated in the medium and one or more soaks are purified from the medium. It also refers to procedures for the separation and purification of lipid-containing agents from culture media, their use as pharmaceutical active substances, particularly Gram-positive bacteria for antibacterial purposes, and the action plan DSM 7.358 for the preparation of the above-mentioned dipping agents. A modified human tnfal molecule can release neutralizing antibody to untrained human tnfal,After the modified tnfal molecule was applied to a human host, at least a portion of the peptide in the human tnfal molecule was replaced by a psychedelic drug known to contain the top of the major immune T cells or a broken form of the molecule containing epinephrine. The major immune component, and one or two flanking regions of the human tnfal molecule, including at least the top of one tnfal B cell, where the amino acid sequence of the pre beta membrane is significantly altered by the substitute,In any connected loop and / or any B ribbon,I or D of the next test board. Tnfal vaccine can be made from modified human tnfal molecules or DNA used for coding, and drug acceptable additives can be used to prevent or treat chronic flammable diseases, such as arthritis, flammability diseases, cancer, sclerosis, diabetes, and psychosis, Osteoporosis or asthma
机译:1.制备一种或多种浸透剂的方法,其特征在于将这些浸透剂发酵并合成到含有肌动蛋白sp的培养基中;直到在培养基中积累一种或多种浸透剂,并从其中纯化一种或多种浸透剂。中。它还涉及从培养基中分离和纯化含脂质试剂的程序,将其用作药物活性物质,特别是用于抗菌目的的革兰氏阳性细菌的方法以及用于制备上述蘸剂的行动计划DSM 7.358代理商。修饰的人tnfal分子可以释放未经训练的人tnfal的中和抗体,将修饰的tnfal分子应用于人宿主后,人tnfal分子中的至少一部分肽被一种已知含有迷迭香顶部的迷幻药替代。主要的免疫T细胞或含有肾上腺素的分子的断裂形式。人tnfal分子的主要免疫成分和一个或两个侧翼区域,至少包括一个tnfal B细胞的顶部,其中前β膜的氨基酸序列在任何连接的环中都被替代物显着改变/或下一个测试板的任何B带,I或D。 Tnfal疫苗可由修饰的人类tnfal分子或用于编码的DNA制成,药物可接受的添加剂可用于预防或治疗慢性易燃疾病,例如关节炎,易燃性疾病,癌症,硬化症,糖尿病和精神病,骨质疏松症或哮喘

著录项

  • 公开/公告号UY23762A1

    专利类型

  • 公开/公告日1994-05-03

    原文格式PDF

  • 申请/专利权人 HOECHST AKTIENGESELLSCHAFT;

    申请/专利号UY19940023762

  • 发明设计人

    申请日1994-04-25

  • 分类号A61P17/06;C12P21/02;A61K38;A61K38/08;A61K38/12;A61P3/10;A61P19/02;A61P31/04;C07K;C07K1/20;C07K7/06;C07K7/60;C07K14/195;C07K14/41;C12N1/20;C12P1/06;C12P21/04;C12R1/045;C12R1/45;

  • 国家 UY

  • 入库时间 2022-08-22 04:44:33

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号